10 December 2025
New formulation of Rybelsus® (oral semaglutide) has replaced the initial formulation
A new formulation of Rybelsus® 1.5mg, 4mg, and 9mg round tablets, with increased bioavailability, has replaced the initial formulation of 3mg, 7mg, and 14mg oval tablets. These two formulations will temporarily co-exist on the market, which may cause confusion and increase the risk of medication errors.
To highlight the change in formulation, updates were made to sections of the semaglutide monograph in BNF, including Indications and dose, and Important safety information.
